

May 27, 2022

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Reg.: Secretarial Compliance Report under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Secretarial Compliance Report duly issued by R&D Company Secretaries, Practising Company Secretaries for the financial year ended March 31, 2022.

This is for your kind information and record please.

cea Bio

Thanking you.

Sincerely yours,

For Panacea Biotec Ltd.

Vinod Goel

Group CFO and Head Legal

& Company Secretary

Encl.: As above

B1 Extn. /G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: D.I.D. +91-11-4167 9015 Fax: +91-11-4167 9070

## R&D

## **COMPANY SECRETARIES**

Secretarial Compliance Report of Panacea Biotec Limited For the financial year ended 31st March, 2022

To, Panacea Biotec Limited Ambala-Chandigarh Highway Lalru- 140501, Punjab.

We, R & D Company Secretaries have examined:

- (a) all the documents and records made available to us and explanation provided by Panacea Biotec Limited ("the listed entity"),
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity,
- (d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,

For the year ended 31st March, 2022 ("Review Period") in respect of compliance with the provisions of:

- (a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 - Not applicable as the Company has not bought back/ propose to buy back any of its securities during the Review Period;
- (e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 - Not applicable as the Company has not given/ proposed to give any share based employee benefits to the Employees during the Review Period;
- (f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 - Not applicable as the Company has not issued any debt securities during the Review Period;
- (g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013- Not applicable;
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (i) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act, 2013 and dealing with client;

FOR IDENTIFICATION PURPOSES ONLY

785, Pocket - E, Mayur Vihar - II, Delhi 110 091 INDIA • Phone/Fax : 011-2272 530 74301-2488i-4268
E-mail : rndcompanysecretaries@gmail.com

and circulars/ guidelines issued thereunder; and based on the above examination and considering the relaxation granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India due to spread of the COVID-19 pandemic, We hereby report that, during the Review Period:

(a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below:-

Sr. No	(Regulation/ Circulars/ guidelines including	Deviations	Observations/Remarks of the Practising Company Secretary
	specific clause)		

- (b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder insofar as it appears from our examination of those records.
- (c) There are no actions taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:
- (d) The listed entity has taken the following actions to comply with the observations made in previous reports: Not Applicable.

For R&D

Place: Delhi

Date: 26.5.2022

Company Secretaries

Debet ata Deb Nath Partner FCS No. 27775; CP No. : 8612

er Review Certificate No. 1403/2021

UDIN: F007775D000396812

FOR IDENTIFICATION **PURPOSES ONLY** 

acea Bio

Delhi-11